These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 18381962)

  • 21. High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy.
    Treré D; Brighenti E; Donati G; Ceccarelli C; Santini D; Taffurelli M; Montanaro L; Derenzini M
    Ann Oncol; 2009 Nov; 20(11):1818-23. PubMed ID: 19556322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Y-box binding protein, YB-1, as a marker of tumor aggressiveness and response to adjuvant chemotherapy in breast cancer.
    Huang J; Tan PH; Li KB; Matsumoto K; Tsujimoto M; Bay BH
    Int J Oncol; 2005 Mar; 26(3):607-13. PubMed ID: 15703814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n=647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study.
    Willemoe GL; Hertel PB; Bartels A; Jensen MB; Balslev E; Rasmussen BB; Mouridsen H; Ejlertsen B; Brünner N
    Eur J Cancer; 2009 Sep; 45(14):2528-36. PubMed ID: 19535243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms on the disease-free survival of breast cancer patients receiving adjuvant 5-fluorouracil/methotrexate-based therapy.
    Paré L; Altés A; Ramón y Cajal T; Del Rio E; Alonso C; Sedano L; Barnadas A; Baiget M
    Anticancer Drugs; 2007 Aug; 18(7):821-5. PubMed ID: 17581305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy.
    Rudas M; Lehnert M; Huynh A; Jakesz R; Singer C; Lax S; Schippinger W; Dietze O; Greil R; Stiglbauer W; Kwasny W; Grill R; Stierer M; Gnant MF; Filipits M;
    Clin Cancer Res; 2008 Mar; 14(6):1767-74. PubMed ID: 18347178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p53 as a specific prognostic factor in triple-negative breast cancer.
    Chae BJ; Bae JS; Lee A; Park WC; Seo YJ; Song BJ; Kim JS; Jung SS
    Jpn J Clin Oncol; 2009 Apr; 39(4):217-24. PubMed ID: 19304743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay.
    Tanino H; Oura S; Hoffman RM; Kubota T; Furukawa T; Arimoto J; Yoshimasu T; Hirai I; Bessho T; Suzuma T; Sakurai T; Naito Y
    Anticancer Res; 2001; 21(6A):4083-6. PubMed ID: 11911296
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Evaluation of 5-fluorouracil-related genes in breast cancer to predict the effect of adjuvant therapy with CMF].
    Tsunoda Y; Suzuki K; Sakamoto MA; Date Y; Sawada T; Tsunoda A; Kusano M
    Gan To Kagaku Ryoho; 2009 Jan; 36(1):51-5. PubMed ID: 19151563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implications for improved high-dose methotrexate therapeutic effects in cultured human breast cancer and bone marrow cells.
    Bowen D; Southerland WM; Johnson DH; Hawkins M; Hughes DE
    Cancer Detect Prev; 2000; 24(5):452-8. PubMed ID: 11129987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gene expression profilers and conventional clinical markers to predict distant recurrences for premenopausal breast cancer patients after adjuvant chemotherapy.
    Niméus-Malmström E; Ritz C; Edén P; Johnsson A; Ohlsson M; Strand C; Ostberg G; Fernö M; Peterson C
    Eur J Cancer; 2006 Nov; 42(16):2729-37. PubMed ID: 17023159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer.
    Fiegl H; Jones A; Hauser-Kronberger C; Hutarew G; Reitsamer R; Jones RL; Dowsett M; Mueller-Holzner E; Windbichler G; Daxenbichler G; Goebel G; Ensinger C; Jacobs I; Widschwendter M
    Clin Cancer Res; 2008 Jun; 14(11):3494-502. PubMed ID: 18519782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sequential combination chemotherapy in human breast cancer: a basis for increased antineoplastic activity and bone marrow protection.
    Davis JH; Desoto JA; Fryar EB; Southerland WM; Bowen D
    Cell Mol Biol (Noisy-le-grand); 2007 May; 53(3):18-26. PubMed ID: 17531145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts.
    Paulus P; Stanley ER; Schäfer R; Abraham D; Aharinejad S
    Cancer Res; 2006 Apr; 66(8):4349-56. PubMed ID: 16618760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897.
    Ganz PA; Hussey MA; Moinpour CM; Unger JM; Hutchins LF; Dakhil SR; Giguere JK; Goodwin JW; Martino S; Albain KS
    J Clin Oncol; 2008 Mar; 26(8):1223-30. PubMed ID: 18227530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of sigma 1 receptor in human breast cancer.
    Wang B; Rouzier R; Albarracin CT; Sahin A; Wagner P; Yang Y; Smith TL; Meric-Bernstam F; Marcelo Aldaz C; Hortobagyi GN; Pusztai L
    Breast Cancer Res Treat; 2004 Oct; 87(3):205-14. PubMed ID: 15528963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
    Li X; Lewis MT; Huang J; Gutierrez C; Osborne CK; Wu MF; Hilsenbeck SG; Pavlick A; Zhang X; Chamness GC; Wong H; Rosen J; Chang JC
    J Natl Cancer Inst; 2008 May; 100(9):672-9. PubMed ID: 18445819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term outcome of adjuvant chemotherapy cyclophosphamide, mitoxantrone, and fluorouracil in women with breast cancer.
    Kumpulainen EJ; Hirvikoski PP; Johansson RT
    Acta Oncol; 2008; 47(1):120-3. PubMed ID: 18097780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin.
    Rojo F; González-Navarrete I; Bragado R; Dalmases A; Menéndez S; Cortes-Sempere M; Suárez C; Oliva C; Servitja S; Rodriguez-Fanjul V; Sánchez-Pérez I; Campas C; Corominas JM; Tusquets I; Bellosillo B; Serrano S; Perona R; Rovira A; Albanell J
    Clin Cancer Res; 2009 May; 15(10):3530-9. PubMed ID: 19417026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of the high-affinity fluoropyrimidine-preferring nucleoside transporter hCNT1 correlates with decreased disease-free survival in breast cancer.
    Gloeckner-Hofmann K; Guillén-Gómez E; Schmidtgen C; Porstmann R; Ziegler R; Stoss O; Casado FJ; Rüschoff J; Pastor-Anglada M
    Oncology; 2006; 70(3):238-44. PubMed ID: 16837820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
    Jiang Y; Tong D; Lou G; Zhang Y; Geng J
    Pathobiology; 2008; 75(4):244-51. PubMed ID: 18580070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.